Publications by authors named "Francisco J Esteva"

100Publications

Validation of plasma metabolites associated with breast cancer risk among Mexican Americans.

Cancer Epidemiol 2020 Sep 30;69:101826. Epub 2020 Sep 30.

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canep.2020.101826DOI Listing
September 2020

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

N Engl J Med 2020 02 11;382(6):514-524. Epub 2019 Dec 11.

From the David Geffen School of Medicine at UCLA, Los Angeles (D.J.S.); Multidisciplinary Breast Center, Universitair Ziekenhuis Leuven, Leuven (P.N.), and Centre Hospitalier Universitaire Liège and Liege University, Liege (G.J.) - all in Belgium; the British Columbia Cancer Agency, Vancouver, Canada (S.C.); University Hospital Erlangen, Comprehensive Cancer Center Erlangen-European Metropolitan Region of Nuremberg, and Department of Gynecology and Obstetrics, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen (P.A.F.), and the Practice for Hematology and Internal Oncology, Velbert (A.N.) - all in Germany; Istituto Nazionale Tumori Fondazione G. Pascale, Naples (M.D.L.), and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (G.V.B.) - both in Italy; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea (S.-A.I.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); New York University Langone Health, New York (F.J.E.); Instituto de Investigación Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.), and Hospital Universitario Virgen Macarena, Department of Medicine, Universidad de Sevilla, Seville (L.D.C.-M.) - both in Spain; Netherlands Cancer Institute-Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Highlands Oncology Group, Fayetteville, AR (J.T.B.); Institut Régional du Cancer, Strasbourg, France (X.P.); Novartis Pharmaceuticals, East Hanover, NJ (M.S., A.C., K.R.-L.); and Novartis Pharma, Basel, Switzerland (Y.W., T.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1911149DOI Listing
February 2020

Are Biosimilars the Future of Oncology and Haematology?

Drugs 2019 Oct;79(15):1609-1624

Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-019-01193-yDOI Listing
October 2019

Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.

Clin Cancer Res 2019 12 12;25(24):7388-7395. Epub 2019 Sep 12.

Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0463DOI Listing
December 2019

Clinical development of CT-P6 in HER2 positive breast cancer.

Expert Opin Biol Ther 2019 10 11;19(10):987-992. Epub 2019 Sep 11.

Division of Hematology/Oncology, Perlmutter Cancer Center at NYU Langone Health , New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1665019DOI Listing
October 2019

Correction to: Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.

Breast Cancer Res Treat 2019 08;176(3):697

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05292-yDOI Listing
August 2019

Immunotherapy and targeted therapy combinations in metastatic breast cancer.

Lancet Oncol 2019 03;20(3):e175-e186

Yale School of Medicine, Yale Cancer Center, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30026-9DOI Listing
March 2019

Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.

Breast Cancer Res Treat 2019 Aug 15;176(3):687-696. Epub 2019 Feb 15.

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05165-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588417PMC
August 2019

Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.

Breast Cancer Res Treat 2019 Jan 19;173(2):329-341. Epub 2018 Oct 19.

Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-018-5005-6
Publisher Site
http://dx.doi.org/10.1007/s10549-018-5005-6DOI Listing
January 2019

A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β.

Invest New Drugs 2018 12 11;36(6):1103-1109. Epub 2018 Oct 11.

Department of Breast Medical Oncology, Dan L. Duncan Building (CPB5.3542), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-018-0672-z
Publisher Site
http://dx.doi.org/10.1007/s10637-018-0672-zDOI Listing
December 2018

Antibody-drug conjugates in triple negative breast cancer.

Future Oncol 2018 Oct 3;14(25):2651-2661. Epub 2018 Sep 3.

Perlmutter Cancer Center at New York University Langone Health, New York, NY 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0131DOI Listing
October 2018

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.

J Clin Oncol 2018 09 25;36(27):2804-2807. Epub 2018 Jun 25.

Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy E. Davidson, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Sharon H. Giordano, University of Texas MD Anderson Cancer Center, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Ian E. Krop, Eric P. Winer, and Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.2713DOI Listing
September 2018

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.

J Clin Oncol 2018 09 25;36(26):2736-2740. Epub 2018 Jun 25.

Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Ian E. Krop, Nancy U. Lin, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Jennifer Levinson, Ponte Vedra Beach; Naren Ramakrishna, Orlando Health University of Florida Health Cancer Center, Orlando, FL; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.2697DOI Listing
September 2018

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

J Clin Oncol 2018 08 3;36(24):2465-2472. Epub 2018 Jun 3.

Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.9909
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.9909DOI Listing
August 2018

Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.

Future Oncol 2018 Aug 27;14(19):1909-1919. Epub 2018 Feb 27.

Department of Cancer Medicine and Medical Oncology, Imperial College & Imperial College Healthcare NHS Trust, London, UK.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2017-0679
Publisher Site
http://dx.doi.org/10.2217/fon-2017-0679DOI Listing
August 2018

A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.

Cancer Chemother Pharmacol 2018 03 12;81(3):505-514. Epub 2018 Jan 12.

CELLTRION Inc, 23 Academy-ro, Yeonsu-gu, Incheon, 22014, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3510-7DOI Listing
March 2018

DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer.

Oncotarget 2017 Sep 24;8(44):77207-77218. Epub 2017 Aug 24.

Semmelweis University 2nd Department of Pediatrics, Budapest, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.20430DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652774PMC
September 2017

Clinical utility of gene-expression signatures in early stage breast cancer.

Nat Rev Clin Oncol 2017 Oct 31;14(10):595-610. Epub 2017 May 31.

Division of Hematology/Oncology, Perlmutter Cancer Center, New York University Langone Medical Center, 160 East 34th Street, New York, New York 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.74DOI Listing
October 2017

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.

J Cancer Res Clin Oncol 2017 Jul 28;143(7):1255-1262. Epub 2017 Feb 28.

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-017-2358-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486569PMC
July 2017

Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype.

Sci Rep 2017 02 6;7:41960. Epub 2017 Feb 6.

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep41960DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292751PMC
February 2017

Biosimilars: Here and Now.

Am Soc Clin Oncol Educ Book 2016 ;35:e151-7

From the U.S. Food and Drug Administration, Silver Spring, MD; New York University Clinical Cancer Center, New York, NY; Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_155954DOI Listing
January 2017

Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma.

Br J Cancer 2015 Sep 22;113(7):1003-9. Epub 2015 Sep 22.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2015.308DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651124PMC
September 2015

Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?

Curr Oncol Rep 2015 Oct;17(10):46

Hofstra-North Shore LIJ School of Medicine, Monter Cancer Center, 450 Lakeville Road, Lake Success, NY, 11042, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-015-0471-zDOI Listing
October 2015

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:
Ayalew Tefferi Hagop Kantarjian S Vincent Rajkumar Lawrence H Baker Jan L Abkowitz John W Adamson Ranjana Hira Advani James Allison Karen H Antman Robert C Bast John M Bennett Edward J Benz Nancy Berliner Joseph Bertino Ravi Bhatia Smita Bhatia Deepa Bhojwani Charles D Blanke Clara D Bloomfield Linda Bosserman Hal E Broxmeyer John C Byrd Fernando Cabanillas George Peter Canellos Bruce A Chabner Asher Chanan-Khan Bruce Cheson Bayard Clarkson Susan L Cohn Gerardo Colon-Otero Jorge Cortes Steven Coutre Massimo Cristofanilli Walter J Curran George Q Daley Daniel J DeAngelo H Joachim Deeg Lawrence H Einhorn Harry P Erba Francisco J Esteva Elihu Estey Isaiah J Fidler James Foran Stephen Forman Emil Freireich Charles Fuchs James N George Morie A Gertz Sergio Giralt Harvey Golomb Peter Greenberg Jordan Gutterman Robert I Handin Samuel Hellman Paulo Marcelo Hoff Ronald Hoffman Waun Ki Hong Mary Horowitz Gabriel N Hortobagyi Clifford Hudis Jean Pierre Issa Bruce Evan Johnson Philip W Kantoff Kenneth Kaushansky David Khayat Fadlo R Khuri Thomas J Kipps Margaret Kripke Robert A Kyle Richard A Larson Theodore S Lawrence Ross Levine Michael P Link Scott M Lippman Sagar Lonial Gary H Lyman Maurie Markman John Mendelsohn Neal J Meropol Yoav Messinger Therese M Mulvey Susan O'Brien Roman Perez-Soler Raphael Pollock Josef Prchal Oliver Press Jerald Radich Kanti Rai Saul A Rosenberg Jacob M Rowe Hope Rugo Carolyn D Runowicz Brenda M Sandmaier Alan Saven Andrew I Schafer Charles Schiffer Mikkael A Sekeres Richard T Silver Lillian L Siu David P Steensma F Marc Stewart Wendy Stock Richard Stone Rainer Storb Louise C Strong Martin S Tallman Michael Thompson Naoto T Ueno Richard A Van Etten Julie M Vose Peter H Wiernik Eric P Winer Anas Younes Andrew D Zelenetz Charles A LeMaistre

Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365030PMC
August 2015

Genomic Signatures in Breast Cancer: Limitations of Available Predictive Data and the Importance of Prognosis.

Clin Adv Hematol Oncol 2015 Jun;13(6 Suppl 6):25-31

New York University Langone Medical Center, New York, New York.

View Article

Download full-text PDF

Source
June 2015

What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?

Am Soc Clin Oncol Educ Book 2015 :e117-25

From the Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; National Cancer Institute at the National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e117DOI Listing
February 2016

CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.

Breast Cancer Res Treat 2015 Jun 14;151(3):501-13. Epub 2015 May 14.

Departments of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3414-3DOI Listing
June 2015

Circulating tumor cell analysis in metastatic triple-negative breast cancers.

Clin Cancer Res 2015 Mar 18;21(5):1098-105. Epub 2014 Dec 18.

University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1948DOI Listing
March 2015

Genome-based risk prediction for early stage breast cancer.

Oncologist 2014 Oct 3;19(10):1019-27. Epub 2014 Sep 3.

Division of Hematology/Oncology, Laura and Isaac Perlmutter Cancer Center, and Genome Technology Center, New York University Langone Medical Center, New York, New York, USA

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2014-0124DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200995PMC
October 2014

Leptomeningeal disease and breast cancer: the importance of tumor subtype.

Breast Cancer Res Treat 2014 Aug 20;146(3):477-86. Epub 2014 Jul 20.

Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-3054-zDOI Listing
August 2014

Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.

J Natl Cancer Inst 2014 Jul 23;106(7). Epub 2014 Jun 23.

Affiliations of authors: University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX (GV-T, LPh, FZ, P-CC, J-HS, HHC, CG, CC, FJE, M-HL, S-CJY); Cancer Biology Graduate Program (GV-T, P-CC, J-HS, HHC, CC, M-HL), Genes and Development Graduate Program (CG, M-HL); Department of Molecular and Cellular Oncology (EF-M, GV-T, LPh, FZ, P-CC, J-HS, HHC, RZ, JC, CG, CC, FJE, M-HL), Department of Breast Medical Oncology (FJE, GNH, LPu); Department of Biostatistics (JE), Department of Bioinformatics and Computational Biology (YQ); Department of Pathology (YZ, YW, WFS); Department of Emergency Medicine (J-SC, S-CJY), and Department of Endocrine Neoplasia and Hormonal Disorders (S-CJY), The University of Texas MD Anderson Cancer Center, Houston, TX; Center for Cancer & Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, TX (YL, WLM); Present address: Breast Cancer Program, Yale Cancer Center, New Haven, CT (LPu).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110474PMC
July 2014

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.

J Clin Oncol 2014 Jul 5;32(19):2100-8. Epub 2014 May 5.

Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Edith A. Perez, Mayo Clinic, Jacksonville; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Cancer Institute, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, PeaceHealth St Joseph Cancer Center, Bellingham, WA; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Sharon H. Giordano and Ana M. Gonzalez-Angulo, University of Texas MD Anderson Cancer Center, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Ian Krop, Eric P. Winter, and Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/32/19/2100.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.54.0955
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.0955DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366342PMC
July 2014

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.

J Clin Oncol 2014 Jul 5;32(19):2078-99. Epub 2014 May 5.

Sharon H. Giordano and Ana M. Gonzalez-Angulo, University of Texas MD Anderson Cancer Center, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Cancer Institute, New York, NY; Jennie R. Crews, PeaceHealth St Joseph Cancer Center, Bellingham, WA; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Ian Krop, Nancy U. Lin, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Jennifer Levinson, Ponte Vedra Beach; Edith A. Perez, Mayo Clinic, Jacksonville; Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando, FL; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.0948DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076031PMC
July 2014

Pertuzumab in the treatment of HER2+ breast cancer.

J Natl Compr Canc Netw 2014 Apr;12(4):591-8

From New York University Cancer Institute, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0059DOI Listing
April 2014

Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.

Cell Res 2014 May 28;24(5):542-59. Epub 2014 Mar 28.

1] Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA [2] Cancer Biology Program, Graduate School of Biomedical Sciences-Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/cr.2014.37DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011340PMC
May 2014

Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab.

Oncologist 2014 Mar 17;19(3):228-34. Epub 2014 Feb 17.

Department of Pharmacy, Banner MD Anderson Cancer Center, Gilbert, Arizona, USA; Division of Pharmacy and Departments of Biostatistics and NYU Cancer Institute, New York University Langone Medical Center, New York, New York, USA; Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0286DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958456PMC
March 2014

Circulating proteolytic products of carboxypeptidase N for early detection of breast cancer.

Clin Chem 2014 Jan 21;60(1):233-42. Epub 2013 Oct 21.

Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2013.211953DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038544PMC
January 2014

Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer.

Int J Cancer 2014 Feb 13;134(3):587-95. Epub 2013 Sep 13.

Department of Veterinary Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.28389DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191919PMC
February 2014

Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer.

Breast Cancer Res Treat 2013 Jan 15;137(2):631-6. Epub 2012 Dec 15.

Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-012-2374-0
Publisher Site
http://dx.doi.org/10.1007/s10549-012-2374-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867793PMC
January 2013

Effect of HER2 status on distant recurrence in early stage breast cancer.

Breast Cancer Res Treat 2013 Jan 6;137(2):449-55. Epub 2012 Dec 6.

Departments of Biostatistics (KRH) and Breast Medical Oncology (FJE), The University of Texas M.D. Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-012-2366-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544467PMC
January 2013

Speech prosthesis aspiration.

Emerg Med J 2013 Jan 15;30(1):85. Epub 2012 Apr 15.

Department of Pulmonary Medicine, Unit 1462, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/emermed-2012-201325DOI Listing
January 2013

Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.

Proc Natl Acad Sci U S A 2012 Apr 28;109(15):5832-7. Epub 2012 Mar 28.

Division of Cell and Molecular Biology, Toronto General Research Institute, University Health Network, Toronto, ON, Canada M5G 2M9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1201105109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326451PMC
April 2012

Altered expression of sialylated glycoproteins in breast cancer using hydrazide chemistry and mass spectrometry.

Mol Cell Proteomics 2012 Jun 7;11(6):M111.011403. Epub 2012 Feb 7.

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/mcp.M111.011403DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433893PMC
June 2012

MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.

Mol Cancer Ther 2012 Feb 5;11(2):360-9. Epub 2011 Dec 5.

Breast Cancer Translational Research Laboratory, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0400DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320047PMC
February 2012

Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer.

Cancer Prev Res (Phila) 2012 Feb 18;5(2):276-82. Epub 2011 Nov 18.

Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-11-0346DOI Listing
February 2012

Herceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necrosis.

PLoS One 2011 10;6(8):e23270. Epub 2011 Aug 10.

Department of Pediatric Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0023270PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154407PMC
December 2011

Serum CD44 levels and overall survival in patients with HER2-positive breast cancer.

Breast Cancer Res Treat 2011 Dec 10;130(3):1029-36. Epub 2011 Aug 10.

Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-011-1691-zDOI Listing
December 2011

Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.

Breast Cancer Res 2010 16;12(6):R96. Epub 2010 Nov 16.

Department of Breast Medical Oncology, The University of Texas M, D, Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2777DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046439PMC
September 2011

Blood peptidome-degradome profile of breast cancer.

PLoS One 2010 Oct 18;5(10):e13133. Epub 2010 Oct 18.

Biological Science Division, Pacific Northwest National Laboratory, Richland, Washington, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0013133PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956627PMC
October 2010

Helicobacter pylori bacteremia with sepsis syndrome.

J Clin Microbiol 2010 Dec 22;48(12):4661-3. Epub 2010 Sep 22.

Department of Laboratory Medicine, Unit 84, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/JCM.01481-10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008481PMC
December 2010

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Am J Pathol 2010 Oct 2;177(4):1647-56. Epub 2010 Sep 2.

Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2353/ajpath.2010.090885DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947262PMC
October 2010

Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.

Cancer Res 2010 Feb 26;70(3):1204-14. Epub 2010 Jan 26.

Departments of Pathology and Obstetrics and Gynecology, University of Colorado Denver School of Medicine, Aurora, Colorado 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-09-3321DOI Listing
February 2010

Molecular predictors of response to trastuzumab and lapatinib in breast cancer.

Nat Rev Clin Oncol 2010 Feb 22;7(2):98-107. Epub 2009 Dec 22.

Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2009.216DOI Listing
February 2010

Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.

Clin Cancer Res 2009 Nov 13;15(21):6639-48. Epub 2009 Oct 13.

Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0951DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783487PMC
November 2009

Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.

Breast Cancer Res 2009 15;11(4):207. Epub 2009 Jul 15.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2324DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750101PMC
February 2010

Early breast cancer.

Lancet 2009 Apr;373(9673):1463-79

Cambridge Breast Unit, Addenbrookes Hospital and University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(09)60316-0DOI Listing
April 2009

Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer.

Oncologist 2008 Dec 17;13(12):1224-34. Epub 2008 Dec 17.

Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2008-0112DOI Listing
December 2008

Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.

Clin Cancer Res 2008 Dec;14(23):7909-16

Department of Breast Medical Oncology, Pathology, Surgical Oncology, Radiation Oncology and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-1104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375958PMC
December 2008

Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.

J Mammary Gland Biol Neoplasia 2008 Dec 25;13(4):485-98. Epub 2008 Nov 25.

Departments of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10911-008-9107-3DOI Listing
December 2008

Her2-positive breast cancer: herceptin and beyond.

Eur J Cancer 2008 Dec 18;44(18):2806-12. Epub 2008 Nov 18.

Department of Cancer Medicine, UT MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2008.09.013DOI Listing
December 2008

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.

Cancer 2008 Sep;113(6):1294-301

Department of Hematology-Oncology, Penn State Hershey Cancer Center, Penn State University/Hershey Medical Center, Hershey, Pennsylvania 17033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.23689DOI Listing
September 2008

Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.

Mol Cancer Ther 2008 Jul;7(7):1846-50

Department of Breast Medical Oncology, Unit 1354, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0168DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2525738PMC
July 2008